HAYWARD, Calif., Aug. 1, 2012 /PRNewswire/ -- Solta Medical,
Inc. (NASDAQ: SLTM) today announced that it has commenced an
underwritten public offering of its common stock. Canaccord
Genuity is acting as sole book-running manager and Roth Capital
Partners is acting as co-manager. Solta Medical expects to
grant the underwriters a 30-day option to purchase up to an
additional 15 percent of the shares of common stock offered in the
public offering solely to cover over-allotments, if any. The
offering is subject to customary conditions and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Solta Medical currently intends to use the net proceeds from the
offering for general corporate purposes.
The offering is being made pursuant to a registration statement
(File No. 333-181074) previously filed with and declared effective
by the Securities and Exchange Commission, or SEC. A
prospectus supplement and accompanying prospectus describing the
terms of the offering will be filed with the SEC. When
available, copies of the prospectus supplement and accompanying
prospectus may be obtained by contacting Canaccord Genuity Inc.,
Attention: Syndicate Department, 99 High Street, 12th Floor,
Boston, Massachusetts 02110, or by
telephone at (617) 371-3900. Electronic copies of the
prospectus supplement and accompanying prospectus will also be
available free of charge on the website of the SEC at
www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
About Solta Medical
Solta Medical, Inc. is a global leader in the medical aesthetics
market providing innovative, safe, and effective solutions for
patients that enhance and expand the practice of medical aesthetics
for physicians. The company offers products to address a
range of skin issues under the industry´s six premier brands:
Thermage®, Fraxel®, Liposonix®, Isolaz®, CLARO® and Clear +
Brilliant®. Thermage is an innovative, non-invasive
radiofrequency procedure for tightening and contouring skin.
As the leader in fractional laser technology, Fraxel delivers
minimally invasive clinical solutions to resurface aging and sun
damaged skin. The Liposonix system uses advanced
high–intensity focused ultrasound (HIFU) technology to permanently
destroy targeted fat just beneath the skin in the treatment areas
of the abdomen and flanks as a noninvasive, nonsurgical approach to
aesthetic waist circumference reduction. Isolaz was the first
laser or light based system indicated for the treatment of
inflammatory acne, comedonal acne, pustular acne, and
mild–to–moderate inflammatory acne. CLARO is a personal care
acne system that is the first FDA cleared over–the–counter IPL
device that uses a powerful combination of both heat and light to
clear skin quickly and naturally. Clear + Brilliant is a
unique, cost–effective treatment that utilizes safe, fractional
laser technology to correct and prevent early signs of aging and is
FDA cleared and CE marked. Since 2002, over one million
Thermage, Fraxel and Isolaz procedures have been performed in over
100 countries. For more information about Solta Medical, call
1-877-782-2286 or log on to www.Solta.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding the completion of the public
offering of common stock described above. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. These statements are
based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those
described in the forward-looking statements, including, among
others, the ability to manage successfully and complete the public
offering, general economic and/or market conditions and the factors
set forth in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year ended
December 31, 2011, the Company's
Quarterly Report on Form 10-Q for the quarter ended
March 31, 2012, the Company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and the prospectus supplement
related to this public offering. The Company undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable law.
SOURCE Solta Medical, Inc.